Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015 South Africa Thoracic Society Conference.
Cipla Global Head of Respiratory Frank Pieters commented, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
Cipla Medpro CEO Paul Miller said, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their obstructive airway disease. Synchrobreathe is in line with Cipla’s commitment to bring innovative products and inhalers to best fit physicians’ and patients’ needs, thereby advancing healthcare for all. Synchrobreathe is expected to reach the market in the current year.”
Read the Cipla press release.
